Through a genome-wide association study (GWAS), circulating FGF21 has been identified as possessing a strong causal effect on improved hyperlipidemia and liver function biomarkers including fibrosis (Larsson et al., 2022). The gene discussed is FGF21; the disease is hyperlipidemia.